Immunoglobulin replacement therapy in secondary hypogammaglobulinemia

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Compagno, Nicolò ^a   Malipiero, Giacomo ^a   Cinetto, Francesco ^a   Agostini, Carlo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bone marrow transplantation; Chronic lymphocytic leukemia; Immunoglobulin replacement therapy; Multiple myeloma; Secondary hypogammaglobulinemia; Solid organ transplantation; Subcutaneous immunoglobulins

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BELIMUMAB; CARBAMAZEPINE; CD20 ANTIBODY; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; DASATINIB; FLUDARABINE; GOLD SALT; IMATINIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAMIPRIL; RITUXIMAB; STEROID; VALPROIC ACID;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY RESPONSE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNE DEFICIENCY; IATROGENIC DISEASE; IMMUNE DYSREGULATION; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; ORGAN TRANSPLANTATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; SHORT SURVEY; SUBCUTANEOUS IMMUNOTHERAPY; SUBSTITUTION THERAPY; T LYMPHOCYTE; THYMOMA;

EID: 84920085380     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00626     Document Type: Short Survey

References (68)

1. Oscier D, Dearden C, Eren E, Erem E, Fegan C, Follows G, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol (2012) 159:541-64. doi: 10.1111/bjh.12067
2. Ravandi F, O'Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother (2006) 55(2):197-209. doi:10.1007/s00262-005-0015-8
3. Sinisalo M, Aittoniemi J, Koski T, Tobin G, Thunberg U, Sundstrom C, et al. Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status. Leuk Lymphoma (2004) 45(12):2451-4. doi:10.1080/10428190400007763
4. Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol (2010) 23:145-53. doi:10.1016/j.beha.2009.12.004
5. Egerer G, Hensel M, Ho AD. Infectious complications in chronic lymphoid malignancy. Curr Treat Options Oncol (2001) 2:237-44. doi:10.1007/s11864-001-0037-1
6. Raanani P, Paul M, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev (2008) (4):CD006501. doi:10.1002/14651858.CD006501.pub2.
7. Anderson D, Ali K, Blanchette V, Brouwers M, Couban S, Radmoor P, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev (2007) 21:S9-56. doi:10.1016/j.tmrv.2007.01.001
8. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol (2006) 117:S525-53. doi:10.1016/j.jaci.2006.01.015
9. Compagno N, Cinetto F, Semenzato G, Agostini C. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica (2014) 99(6):1101-6. doi:10.3324/haematol.2013.101261
10. Francis S, Karanth M, Pratt G, Starczynski J, Hooper L, Fegan C, et al. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. Cancer (2006) 107:1023-33. doi:10.1002/cncr.22094
11. Hensel M, Kornacker M, Yammeni S, Egerer G, Ho AD. Disease activity and pretreatment, rather than hypogammaglobulinaemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukaemia. Br J Haematol (2003) 122:600-6. doi:10.1046/j.1365-2141.2003.04497.x
12. Dhalla F, Lucas M, Schuh A, Bhole M, Jain R, Patel SY, et al. Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin? J Clin Immunol (2014) 34(3):277-82. doi:10.1007/s10875-014-9995-5
13. Freeman JA, Crassini KR, Best OG, Forsyth CJ, Mackinlay NJ, Han P, et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma (2013) 54:99-104. doi:10.3109/10428194.2012.706285
14. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis (2009) 49(8):1211-25. doi:10.1086/605664
15. Kyrtsonis MC, Mouzaki A, Maniatis A. Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM). Med Oncol (1999) 16(2):73-7. doi:10.1007/BF02785839
16. Ludwig H, Zojer N. Supportive care in multiple myeloma. Best Pract Res Clin Haematol (2007) 20(4):817-35. doi:10.1016/j.beha.2007.10.001
17. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet (1994) 343(8905):1059-63. doi:10.1016/S0140-6736(94)90180-5
18. Blombery P, Prince HM, Worth LJ, Main J, Yang M, Wood EM, et al. Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications. Ann Hematol (2011) 90(10):1167-72. doi:10.1007/s00277-011-1275-3
19. Snowden JA, Ahmedzai SH, Ashcroft J, D'Sa S, Littlewood T, Low E, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol (2011) 154(1):76-103. doi:10.1111/j.1365-2141.2011.08574.x
20. Avivi I, Stroopinsky D, Katz T. Anti-CD20 monoclonal antibodies: beyond B-cells. Blood Rev (2013) 27(5):217-23. doi:10.1016/j.blre.2013.07.002
21. Kano G, Nakatani T, Yagi K, Sakamoto I, Imamura T. Complicated pathophysiology behind rituximab-induced persistent hypogammaglobulinemia. Immunol Lett (2014) 159(1-2):76-8. doi:10.1016/j.imlet.2013.10.005
22. Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol (2009) 146(1):120-2. doi:10.1111/j.1365-2141.2009.07715.x
23. De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (2012) 51(5):833-40. doi:10.1093/rheumatology/ker417
24. Levy R, Mahevas M, Galicier L, Boutboul D, Moroch J, Loustau V, et al. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature. Autoimmun Rev (2014) 13(10):1055-63. doi:10.1016/j.autrev.2014.08.036
25. Makatsori M, Kiani-Alikhan S, Manson AL, Verma N, Leandro M, Gurugama NP, et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM (2014) 107(10):821-8. doi:10.1093/qjmed/hcu094
26. Miles SA, McGratten M. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol (2005) 23(1):247-8. doi:10.1200/JCO.2005.05.282
27. Nishio M, Endo T, Fujimoto K, Sato N, Sakai T, Obara M, et al. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol (2005) 75(6):527-9. doi:10.1111/j.1600-0609.2005.00552.x
28. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk (2013) 13(2):106-11. doi:10.1016/j.clml.2012.11.011
29. Duraisingham SS, Buckland M, Dempster J, Lorenzo L, Grigoriadou S, Longhurst HJ. Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement. PLoS One (2014) 9(6):e100324. doi:10.1371/journal.pone.0100324
30. Kanbayashi Y, Nomura K, Fujimoto Y, Yamashita M, Ohshiro M, Okamoto K, et al. Risk factors for infection in haematology patients treated with rituximab. Eur J Haematol (2009) 82(1):26-30. doi:10.1111/j.1600-0609.2008.01165.x
31. Diwakar L, Gorrie S, Richter A, Chapman O, Dhillon P, Al-Ghanmi F, et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol (2010) 63(3):275-7. doi:10.1136/jcp.2009.068940
32. Kaplan B, Kopyltsova Y, Khokhar A, Lam F, Bonagura V. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract (2014) 2(5):594-600. doi:10.1016/j.jaip.2014.06.003
33. Mogensen TH, Bernth-Jensen JM, Petersen CC, Petersen MS, Nyvold C, Gadegaard KH, et al. Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with rituximab. BMC Hematol (2013) 13(1):4. doi:10.1186/2052-1839-13-4
34. Nishio M, Endo T, Fujimoto K, Yamamoto S, Obara M, Yamaguchi K, et al. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur J Haematol (2009) 82(2):143-7. doi:10.1111/j.1600-0609.2008.01174.x
35. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis (2011) 15(1):e2-16. doi:10.1016/j.ijid.2010.03.025
36. Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol (2006) 17(9):1424-7. doi:10.1093/annonc/mdl141
37. Imashuku S, Teramura T, Morimoto A, Naya M, Kuroda H. Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproliferative disease. Bone Marrow Transplant (2004) 33(1):129-30. doi:10.1038/sj.bmt.1704307
38. Lim SH, Zhang Y, Wang Z, Esler WV, Beggs D, Pruitt B, et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant (2005) 35(2):207-8. doi:10.1038/sj.bmt.1704742
39. Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant (2006) 38(6):433-6. doi:10.1038/sj.bmt.1705463
40. Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol (2006) 77(3):226-32. doi:10.1111/j.1600-0609.2006.00693.x
41. Witzens-Harig M, Foa R, Di Rocco A, van Hazel G, Chamone DF, Rowe JM, et al. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol (2014) 93(10):1717-24. doi:10.1007/s00277-014-2103-3
42. Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology (2013) 52(11):2041-7. doi:10.1093/rheumatology/ket257
43. VenhoffN, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One (2012) 7(5):e37626. doi:10.1371/journal.pone.0037626
44. Marco H, Smith RM, Jones RB, Guerry MJ, Catapano F, Burns S, et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord (2014) 15:178. doi:10.1186/1471-2474-15-178
45. van Vollenhoven RF, Emery P, Bingham CO III, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis (2013) 72(9):1496-502. doi:10.1136/annrheumdis-2012-201956
46. Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Isola M, Buttignol S, et al. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia. Am J Hematol (2012) 87(9):886-9. doi:10.1002/ajh.23272
47. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med (2007) 146(1):25-33. doi:10.7326/0003-4819-146-1-200701020-00006
48. Arai Y, Yamashita K, Mizugishi K, Kondo T, Kitano T, Hishizawa M, et al. Risk factors for hypogammaglobulinemia after allo-SCT. Bone Marrow Transplant (2014) 49(6):859-61. doi:10.1038/bmt.2014.28
49. Norlin AC, SairafiD, Mattsson J, Ljungman P, Ringden O, Remberger M. Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival. Bone Marrow Transplant (2008) 41(3):267-73. doi:10.1038/sj.bmt.1705892
50. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 15(10):1143-238. doi:10.1016/j.bbmt.2009.06.019
51. Sundin M, Nordin K, Jostemyr Y, Winiarski J. Subcutaneous IgG replacement after pediatric SCT. Pediatr Transplant (2012) 16(8):866-71. doi:10.1111/j.1399-3046.2012.01783.x
52. Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant (2013) 13(10):2601-10. doi:10.1111/ajt.12401
53. Carbone J, Sarmiento E, Del Pozo N, Rodriguez-Molina JJ, Navarro J, Fernandez-Yanez J, et al. Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections. Clin Transplant (2012) 26(3):E277-83. doi:10.1111/j.1399-0012.2012.01653.x
54. Yamani MH, Avery R, Mawhorter S, Young JB, McNeill A, Cook DJ, et al. Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes. Transpl Infect Dis (2001) 3(Suppl 2):40-3. doi:10.1034/j.1399-3062.2001.00008.x
55. Shankar T, Gribowicz J, Crespo M, Silveira FP, Pilewski J, Petrov AA. Subcutaneous IgG replacement therapy is safe and well tolerated in lung transplant recipients. Int Immunopharmacol (2013) 15(4):752-5. doi:10.1016/j.intimp.2013.02.021
56. Molinaro I, Barbano B, Rosato E, Cianci R, Di Mario F, Quarta S, et al. Safety and infectious prophylaxis of intravenous immunoglobulin in elderly patients with membranous nephropathy. Int J Immunopathol Pharmacol (2014) 27(2): 305-8.
57. Fijolek J, Wiatr E, Demkow U, Orlowsk TM. Immunological disturbances in Good's syndrome. Clin Invest Med (2009) 32(4):E301-6.
58. Wang CH, Chan ED, Perng CL, Chian CF, Chen CW, Perng WC, et al. Intravenous immunoglobulin replacement therapy to prevent pulmonary infection in a patient with Good's syndrome. J Microbiol Immunol Infect (2012). doi:10.1016/j.jmii.2012.09.003
59. Deener A, Mehra A, Bernstein L, Shliozberg J, Rubinstein A. Intravenous gammaglobulin treatment in HIV-1 infection. Immunol Allergy Clin North Am (2008) 28(4):851-9. doi:10.1016/j.iac.2008.06.001
60. Pastori D, Esposito A, Mezzaroma I. Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: a systematic review. Int Rev Immunol (2011) 30(1):44-66. doi:10.3109/08830185.2010.529975
61. The National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med (1991) 325(2):73-80. doi:10.1056/NEJM199107113250201
62. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am (2008) 28(4):779-802.
63. Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am (2008) 28(2):413-37. doi:10.1016/j.iac.2008.01.008
64. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs (2007) 21(2):105-16. doi:10.2165/00063030-200721020-00005
65. Gardulf A, Borte M, Ochs HD, Nicolay U, Vivaglobin Clinical Study Group. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol (2008) 126(1):81-8. doi:10.1016/j.clim.2007.06.009
66. Gardulf A, Nicolay U, Asensio O, Bernatowska E, Bock A, Carvalho BC, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J Clin Immunol (2006) 26(2):177-85. doi:10.1007/s10875-006-9002-x
67. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M, Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol (2006) 26(3):265-73. doi:10.1007/s10875-006-9021-7
68. Borte M, Quinti I, Soresina A, Fernandez-Cruz E, Ritchie B, Schmidt DS, et al. Efficacy and safety of subcutaneous vivaglobin(R) replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol (2011) 31(6):952-61. doi:10.1007/s10875-011-9588-5